Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years, of any gender
• People with a confirmed diagnosis of T-cell acute lymphoblastic leukemia (T-ALL) whose bone marrow or lab tests show the disease is still present, and whose cancer either did not respond to at least 2 cycles of standard treatment, came back within 12 months of first responding to treatment, did not respond to or came back after 2 or more treatment attempts, or came back after a stem cell transplant
• People with a confirmed diagnosis of T-cell lymphoma (including several specific subtypes), who have at least one measurable area of disease detected on scans, and whose cancer did not respond to at least 2 rounds of treatment, showed primary resistance, or came back after a stem cell transplant
• People whose cancer cells test positive for a protein called CD5, confirmed through specific lab tests (flow cytometry or tissue staining)
• People with a general health and activity level rated as reasonably functional (ECOG score of 0, 1, or 2 — confirm with trial site)
• People with a life expectancy of at least 12 weeks
• People whose heart, kidneys, liver, and lungs are functioning at acceptable levels based on specific test results (confirm exact values with trial site)
• People who have no medical reasons preventing blood collection or vein access procedures
• People without severe psychiatric conditions
• People who agree to use effective contraception from the time of joining the trial until at least one year after receiving the trial treatment (where applicable)
• People who have signed an informed consent form, or whose legal guardian has done so on their behalf

Who may not be able to join:

• People who have previously received CAR-NK therapy or any other genetically modified cell therapy
• People whose cancer is currently active in the central nervous system (brain and spinal cord) at the time of screening (prior involvement that has fully resolved after treatment may be acceptable — confirm with trial site)
• People who have received chemotherapy, targeted therapy, or other investigational drugs within 2 weeks or 5 half-lives before screening
• People who have received radiation therapy within 2 weeks before screening
• People with an active or uncontrolled infection within 1 week before screening
• People who have had a stroke or seizure within the past 6 months
• People with active hepatitis B or C virus in their blood, or who test positive for HIV, syphilis, or active tuberculosis
• People with significant heart conditions, including severe heart failure, a heart attack or major heart surgery within the past 6 months, serious irregular heart rhythms, unexplained fainting episodes, or severe disease of the heart muscle
• People with an active or uncontrolled autoimmune disease
• People who have had another type of cancer within the past 5 years (certain fully treated cancers may be exceptions — confirm with trial site)
• People who have received a live vaccine within 4 weeks before screening
• People who are pregnant, breastfeeding, or planning to become pregnant within one year of receiving the trial treatment
• People whom the trial investigators determine to be unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.